title: Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison.
abstract: BACKGROUND
  To compare the efficiency of dexamethasone implants to bevacizumab injections in macular oedema secondary to central retinal vein occlusion.
  
  
  METHODS
  Randomized clinical trial at Cairo University Hospitals.
  
  
  METHODS
  Sixty eyes of 60 newly diagnosed patients with macular oedema secondary to central retinal vein occlusion with best corrected visual acuity 0.3 logMAR (6/12) to counting fingers, no evidence of retinal ischaemia and/or neovascularization on fluorescein angiography and central subfield thickness ≥300 μm on ocular coherence tomography.
  
  
  METHODS
  Patients were randomly assigned (30 eyes each group) to either intravitreal dexamethasone implant or bevacizumab injections repeated whenever needed. Best corrected visual acuity and ocular coherence tomography were done at baseline and monthly for 6 months.
  
  
  METHODS
  Comparing best corrected visual acuity and central foveal subfield thickness between both groups during the 6-month period.
  
  
  RESULTS
  There was no significant difference in best corrected visual acuity between the two groups during the 6 months (P-values > 0.05). The bevacizumab group had a statistically significant thinner central subfield thickness at 1 month (P-value 0.006) and no statistically significant difference for the rest of the 6 months (P-values > 0.05). There was a statistically significant higher intraocular pressure for dexamethasone implant group (compared with bevacizumab) at 3-6 months (P-values < 0.05), respectively.
  
  
  CONCLUSIONS
  Both drugs provided effective best corrected visual acuity improvements and central subfield thickness reductions that showed no statistically significant difference between the two groups.
authors.affiliation: Department of Ophthalmology, Kasr El Aini Hospitals, Cairo University, Cairo, Egypt.
authors.forename: Ahmed S
authors.initials: AS
authors.lastname: Gado
authors.forename: Tamer A
authors.initials: TA
authors.lastname: Macky
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004343:Drug Implants; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D003907:Dexamethasone
keywords: central retinal vein occlusion; dexamethasone implant (Ozurdex); intravitreal bevacizumab (Avastin); macular oedema